The discovery of somatic activating mutations in the BRAF gene in several cancers 5, including approximately 50% of melanomas 6, 7, provided the genetic foundation for the development of targeted treatment approaches for patients with BRAF‐mutant cancers. This evidence concerns the gene BRAF and melanoma.